6th Annual RAS-Targeted Drug Development Summit [09/24/24]

Uniting Large Pharma, Innovative Biotech and Leading Academics to Defeat the Holy Grail Target in Precision Oncology

With tumor and patient heterogeneity, the quest to target the remaining RAS mutants continues, and now more than ever, we are witnessing this industry make great strides in utilizing novel modalities and elucidating mechanisms of resistance. However, treating patients with RAS mutant cancers remains no easy feat, as knowledge gaps persist in improving the depth and durability of response, tackling emerging resistance mechanisms and informing combination strategies to improve the standard-of care for patients in need.

Owing to this, the 6th Annual RAS-Targeted Drug Development Summit returns as the central hub dedicated to every aspect of discovery and development of RAS, from discovery and clinical development through to commercialization, equipping 200+ global RAS leaders with the means to create effective frontline RAS therapies for better patient outcomes.

URLs:

Tickets: https://go.evvnt.com/2464057-2?pid=5248

Brochure: https://go.evvnt.com/2464057-3?pid=5248

Prices:

Conference + Workshop - Drug Developer Pricing: USD 4197.00,

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference + Workshop - Solution and Service Provider Pricing: USD 5097.00,

Conference Only - Solution and Service Provider Pricing: USD 3699.00,

Conference + Workshop - Academic and Non-Profit Pricing: USD 3597.00,

Conference Only - Academic and Non-Profit Pricing: USD 2599.00

Speakers: Ahmadur Rahman, Senior Clinical Director and Clinical Science Lead, Global Oncology Research and Development, Roche, Andrea Wang-Gillam, Chief Medical Officer, Jacobio Pharmaceuticals, Andreas Weiss, Associate Director, Norvartis, Andrew Norris, Co-Founder and Chief Scientific Officer, BCN Biosciences, Bhakti Mehta, Executive Medical Director, Amgen, Bobby Norgard, Senior Scientist, Boehringer Ingelheim, Bradley Quade, Senior Scientist, Nested Therapeutics, Brent Kreider, President, Biomed Valley Discoveries, Brian Lanman, Senior Director - Research, Amgen, Chiara Ambrogio, Associate Professor of Molecular Biology, University of Turin, Chinatsu Sakata-Sakurai, Vice President, Primary Focus Lead, Targeted Protein Degradation, Astellas Pharma, Christopher Hupp, Senior Director - External Innovation, Chemistry, Ipsen, Eric Campeau, Vice President Translational Research, Thryv Therapeutics, Eric Haines, Director - Scientific Cancer Biology, Ikena Oncology, Geoff Oxnard, Vice President, Clinical Development, Global Head, Thoracic Cancer, Loxo@Lilly, Henning Lauterbach, Vice President, Immunology Research and Clinical Biomarkers, Hookipa Pharma, Hetika Patel, Scientist, Kura Oncology, Jan Smith, Chief Scientific Officer, Revolution Medicines, Ji Luo, Senior Investigator and Head, Oncogenic Signaling Section, National Cancer Institute, Joe Klebba, Associate Director, Vividion Therapeutics, John Hayslip, Chief Medical Officer, Verastem, Jonathan Pachter, Chief Scientific Officer, Verastem, Joseph Mancias, Assistant Professor of Radiation Oncology, Harvard Medical School, Kevin Foley, Co-founder and Chief Scientific Officer, Ranok Therapeutics, Kevin Webster, Chief Scientific Officer, Frontier Medicines, Krzysztof Brzozka, Chief Scientific Officer, Executive Vice President, Ryvu Therapeutics, Lynn Kirkpatrick, Chief Executive Officer, PHusis Therapeutics, Madhumita Bogdan, Senior Principal Investigator, Biological Sciences, Deciphera Pharmaceuticals, Markus Vallaster, Vice President - Clinical Development, Affini-T Therapeutics, Naftali Bechar, Senior Vice President - Clinical Development, Inspirna, Nathan Jameson, Senior Scientist, Zentalis Pharmaceuticals, Peter DeMuth, Chief Scientific Officer, Elicio Therapeutics, Qiang Lu, Co-Founder and Chairman, GenFleet Therapeutics, Rafael Rosengarten, Chief Executive Officer, Genialis, Reagan Jarvis, Co-founder, CEO, Anocca, Shailaja Kasibhatla, Senior Vice President, Boundless Bio, Sunanda Singh, Founder and Chief Executive Officer. Singh Biotechnology, Wolfgang Schwede, Principal Scientist, Bayer, Yu Wang, Chief Medical Officer, GenFleet Therapeutics, Zahra Kabiri, Assistant Professor, Duke University

6th Annual RAS-Targeted Drug Development Summit

Share this event